ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Vidpok1	3/15/2016 7:53:07 AM
	Read Replies (1) of 4474

It is increasingly clear that Denner's plan (or lack thereof according to some) has resulted in the recent resurgence in the sp vis a vis the biotech sector indices. The addition of PP and now the new CFO who just coincidentally was instrumental in facilitating another buyout are part of Denners "non plan" which is generating considerable enthusiasm by investors. 113 is on the cusp of becoming bic for its indication and the objective posters on this board project an eventual revenue stream approaching 1B over time for this incredible drug. All the news recently on Ponatinib points to its increasing acceptance and widening list of indications which over time will result in this drug becoming the 2nd line doc for CML and its likely use in conjunction with other treatments resulting in multiple revenue streams over time. Suddenly the talk of a buyout at 9 has ceased. Only a matter of time before the talk of a buyout over 20 returns. Must be because of all the encouragement from the longs here whose wise guidance has led to management's enlightenment.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next